<\/p>\n
Udimax 300<\/strong> is ursodeoxycholic acid (UDCA) 300 mg<\/strong> — a hydrophilic bile acid that is the standard of care for primary biliary cholangitis (PBC), cholesterol gallstones in patients unfit for surgery, intrahepatic cholestasis of pregnancy (ICP), bile-acid diarrhoea, and pruritus of cholestatic liver disease<\/strong>. UDCA reduces cholesterol saturation in bile, replaces toxic hydrophobic bile acids in the bile-acid pool, exerts cytoprotective and anti-apoptotic effects on hepatocytes and cholangiocytes, and stimulates bicarbonate-rich choleresis. Standard adult doses range from 10–15 mg\/kg\/day for PBC and gallstones to 14–30 mg\/kg\/day for cholestasis of pregnancy<\/strong>. WHO-GMP-sertifisert produsent.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n Udimax 300 is supplied from a WHO-GMP-sertifisert produsent<\/strong>. Hver ordre sendes diskret over hele verden og er dekket av v\u00e5r Reshipment Assurance Policy<\/a> — if it does not arrive within 20 business days, we reship at no cost. UDCA has been on the WHO Essential Medicines List for decades and is the cornerstone of medical therapy for cholestatic liver disease.<\/p>\n UDCA is a naturally occurring hydrophilic 7β-hydroxy bile acid (“the bear bile acid”). When taken orally it enriches the bile-acid pool, replacing toxic hydrophobic acids (chenodeoxycholic, lithocholic) that damage cholangiocytes and hepatocytes in cholestasis. Three actions matter clinically: (1) it reduces biliary cholesterol saturation, dissolving cholesterol gallstones over months; (2) it exerts direct cytoprotective and anti-apoptotic effects on liver cells, reducing immune-mediated damage in PBC; (3) it stimulates a bicarbonate-rich “alkaline tide” choleresis, which protects cholangiocytes from the detergent action of hydrophobic bile acids. Onset of biochemical improvement in PBC is typically 2–6 months.<\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
Hvorfor bestille fra MedsBase<\/h3>\n
Mekanisme<\/h2>\n
Indications & doses<\/h2>\n